Global biopharmaceutical leader GSK PLC has entered into a definitive agreement to acquire efimosfermin, a promising ...

Scientists have discovered a possible link between the development of colon cancer and a 'silent' condition that affects more ...

GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the ...

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

The reductions in NIH funding and staff are happening at a time when colorectal cancer cases have been rising among younger ...

Still, with all the medical burdens Maggie bore, with all the indignities she suffered while being poked and prodded and ...

GSK will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline ...

Scientists have discovered a link between early-onset colon cancer and fatty liver disease. Suffered by one in four Americans ...

Ronen Israel and Amrik Shah join an expanded international leadership group at Yaqrit preparing to implement funding streams and build pharmaceutical partnerships to propel the company's drug products ...

LONDON] GSK agreed to buy an experimental medicine to treat liver disease for as much as US$2 billion as the UK drugmaker ...

The drugmaking giant plans to pay $1.2billion upfront to acquire Efirmosfermin from Boston Pharmaceuticals, followed by ...